Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$40.00 -0.2%	$35.80	$21.62 ▼ $41.71	$7.61B	1.1	2.51 million shs	3.26 million shs
BPMC Blueprint Medicines	$128.12 -0.1%	$102.85	$73.04 ▼ $128.34	$8.28B	0.84	1.24 million shs	3.48 million shs
DCPH Deciphera Pharmaceuticals	$25.59	$25.59	$9.90 ▼ $25.61	$2.21B	0.19	1.29 million shs	600 shs
VRNA Verona Pharma PLC American Depositary Share	$90.92 -2.2%	$73.21	$14.14 ▼ $94.45	$7.91B	0.21	1.32 million shs	1.01 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.17%	+2.43%	+18.73%	+17.96%	+44.88%
BPMC Blueprint Medicines	-0.09%	+0.13%	+26.59%	+44.82%	+20.06%
DCPH Deciphera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
VRNA Verona Pharma PLC American Depositary Share	-2.16%	+0.97%	+25.27%	+37.20%	+486.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.6858 of 5 stars	4.5	2.0	0.0	3.9	3.3	3.3	0.6
BPMC Blueprint Medicines	1.0764 of 5 stars	2.1	2.0	0.0	0.0	1.9	0.8	0.6
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma PLC American Depositary Share	2.1514 of 5 stars	2.5	3.0	0.0	0.0	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$56.67	41.67% Upside
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.05% Downside
DCPH Deciphera Pharmaceuticals	0.00	N/A	N/A	N/A
VRNA Verona Pharma PLC American Depositary Share	3.00	Buy	$91.11	0.21% Upside

Current Analyst Ratings Breakdown

Latest DCPH, BPMC, BBIO, and VRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	VRNA Verona Pharma PLC American Depositary Share	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$92.00 ➝ $116.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/11/2025	VRNA Verona Pharma PLC American Depositary Share	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $100.00
6/11/2025	VRNA Verona Pharma PLC American Depositary Share	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$95.00 ➝ $110.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	34.23	N/A	N/A	($7.71) per share	-5.19
BPMC Blueprint Medicines	$508.82M	16.26	N/A	N/A	$4.70 per share	27.26
DCPH Deciphera Pharmaceuticals	$174.91M	12.65	N/A	N/A	$4.38 per share	5.84
VRNA Verona Pharma PLC American Depositary Share	$42.28M	183.07	N/A	N/A	$2.56 per share	35.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.11	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
DCPH Deciphera Pharmaceuticals	-$194.94M	-$2.21	N/A	N/A	N/A	-108.86%	-52.42%	-40.05%	N/A
VRNA Verona Pharma PLC American Depositary Share	-$173.42M	-$2.00	N/A	3,030.67	N/A	N/A	-69.65%	-28.00%	8/6/2025 (Estimated)

Latest DCPH, BPMC, BBIO, and VRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million
4/29/2025	Q1 2025	VRNA Verona Pharma PLC American Depositary Share	-$0.22	$0.27	+$0.49	-$0.16	$41.47 million	$98.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma PLC American Depositary Share	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
BPMC Blueprint Medicines	1.01	2.80	2.75
DCPH Deciphera Pharmaceuticals	N/A	4.19	3.94
VRNA Verona Pharma PLC American Depositary Share	1.07	8.86	8.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BPMC Blueprint Medicines	N/A
DCPH Deciphera Pharmaceuticals	70.96%
VRNA Verona Pharma PLC American Depositary Share	85.88%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BPMC Blueprint Medicines	4.21%
DCPH Deciphera Pharmaceuticals	4.67%
VRNA Verona Pharma PLC American Depositary Share	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
DCPH Deciphera Pharmaceuticals	300	86.48 million	82.44 million	Optionable
VRNA Verona Pharma PLC American Depositary Share	30	85.13 million	81.05 million	Optionable

DCPH, BPMC, BBIO, and VRNA Headlines

Recent News About These Companies

Mission Wealth Management LP Purchases New Stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 19 at 4:02 AM | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells $922,400.00 in Stock

June 18 at 5:56 PM | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives "Buy" Rating from Roth Capital

June 18 at 1:02 PM | marketbeat.com

Traders Purchase Large Volume of Verona Pharma Put Options (NASDAQ:VRNA)

June 17 at 2:31 AM | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Hits New 12-Month High - What's Next?

June 16 at 5:48 PM | marketbeat.com

Traders Purchase High Volume of Verona Pharma Put Options (NASDAQ:VRNA)

June 16 at 11:56 AM | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 400,000 Shares

June 16 at 4:19 AM | americanbankingnews.com

Verona Pharma plc (NASDAQ:VRNA) CFO Sells $4,560,000.00 in Stock

June 16 at 4:19 AM | americanbankingnews.com

Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch

June 14, 2025 | finance.yahoo.com

Verona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in Stock

June 14, 2025 | insidertrades.com

Cantor Fitzgerald Predicts Verona Pharma FY2025 Earnings

June 14, 2025 | americanbankingnews.com

Verona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in Stock

June 13, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 400,000 Shares

June 13, 2025 | marketbeat.com

Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch

June 13, 2025 | insidermonkey.com

Cantor Fitzgerald Estimates Verona Pharma FY2025 Earnings

June 13, 2025 | marketbeat.com

Cantor Fitzgerald Comments on Verona Pharma FY2026 Earnings

June 13, 2025 | americanbankingnews.com

Cantor Fitzgerald Issues Positive Forecast for Verona Pharma (NASDAQ:VRNA) Stock Price

June 13, 2025 | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Trading Up 4.5% on Analyst Upgrade

June 13, 2025 | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Price Target Raised to $110.00 at Jefferies Financial Group

June 12, 2025 | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Shares Up 4.5% on Analyst Upgrade

June 11, 2025 | marketbeat.com

Jefferies Financial Group Issues Positive Forecast for Verona Pharma (NASDAQ:VRNA) Stock Price

June 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCPH, BPMC, BBIO, and VRNA Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$40.00 -0.07 (-0.17%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$40.01 +0.01 (+0.02%)

As of 06/18/2025 08:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Blueprint Medicines NASDAQ:BPMC

$128.12 -0.11 (-0.09%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$128.14 +0.02 (+0.02%)

As of 06/18/2025 07:11 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Deciphera Pharmaceuticals NASDAQ:DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$90.92 -2.01 (-2.16%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$91.06 +0.14 (+0.15%)

As of 06/18/2025 07:14 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time